Rintatolimod

AIM Highlights Ampligen Potential in Pancreatic Cancer

OCALA, Fla. — September 22, 2026 AIM ImmunoTech Inc. highlighted the potential role of Ampligen® (rintatolimod) in pancreatic cancer...

By cGxPwire Editor
September 24, 2026

Bio-Pharma

AIM ImmunoTech Expands Ampligen Patent Protection in Europe and U.K. Through 2041

OCALA, Fla., Sept. 2, 2026 AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharmaceutical company developing Ampligen® (rintatolimod), announced that...

By cGxPwire Editor
September 3, 2026

Bio-Pharma

AIM ImmunoTech Wins U.S. Patent for Ampligen Cancer Therapy

OCALA, Fla., August 31, 2026 AIM ImmunoTech Inc. announced that the U.S. Patent and Trademark Office (USPTO) has granted...

By cGxPwire Editor
September 1, 2026

Bio-Pharma

AIM ImmunoTech Advances Ampligen Toward Phase 3 Cancer Trial

OCALA, Fla., August 10, 2026 AIM ImmunoTech Inc. reported its second-quarter 2026 financial results and highlighted continued progress in...

By cGxPwire Editor
August 12, 2026

Bio-Pharma

AIM ImmunoTech Advances DURIPANC Trial with Final Dosing Milestone

OCALA, Fla., Aug. 3, 2026 AIM ImmunoTech Inc. announced that the final patient has received the last protocol-defined dose...

By cGxPwire Editor
August 4, 2026

Find Jobs Across Pharma, Biotech & Life Sciences

Discover verified job opportunities from top companies worldwide. Apply easily and grow your career in the life sciences industry.

Bio-Pharma

AIM ImmunoTech Advances Ampligen Toward Potential Pivotal Development

OCALA, Fla., June 24, 2026 AIM ImmunoTech Inc. highlighted significant progress across its pancreatic cancer development program, positioning Ampligen®...